Anticancer Effects of Wild Baicalin on Hepatocellular Carcinoma: Downregulation of AKR1B10 and PI3K/AKT Signaling Pathways

Overview

Journal Cancer Manag Res

Publisher Dove Medical Press

Specialty Oncology

Date 2024 May 27

PMID 38800664

Authors

Longjun Sun

Wenjuan Chen

Peixi Zhao

Bin Zhao

Guangyan Lei

Le Han

Yili Zhang

Affiliations

Soon will be listed here.

Abstract

Introduction: Hepatocellular carcinoma (HCC) is a common and deadly malignancy. Traditional Chinese medicine, such as the compound Astragalus (wild Baicalin), has shown promise in improving outcomes for HCC patients. This study aimed to investigate the effects of wild Baicalin on the human hepatoma cell line HepG2 and elucidate the underlying mechanisms, particularly the role of the AKR1B10 and PI3K/AKT signaling pathways.

Methods: HepG2 cells were treated with varying concentrations of wild Baicalin. Cell proliferation, apoptosis, migration, invasion, and cell cycle were evaluated using CCK-8, flow cytometry, scratch, Transwell, and clonogenic assays, respectively. Transcriptome sequencing was performed to analyze gene expression changes induced by wild Baicalin. Differentially expressed genes were identified and analyzed using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. The expression of AKR1B10 and PI3K was validated by qPCR.

Results: Wild Baicalin inhibited HepG2 cell proliferation, induced apoptosis, suppressed migration and invasion, and caused cell cycle arrest in a dose-dependent manner. Transcriptome sequencing revealed 1202 differentially expressed genes, including 486 upregulated and 716 downregulated genes. GO analysis indicated that biological processes were pivotal in the anticancer mechanism of wild Baicalin, while KEGG analysis identified metabolic pathways as the most significantly regulated. AKR1B10 and PI3K, key genes in metabolic pathways, were downregulated by wild Baicalin, which was confirmed by qPCR.

Discussion: The findings suggest that wild Baicalin exhibits potent anticancer effects against HepG2 cells by inducing apoptosis, inhibiting proliferation, migration, and invasion, and causing cell cycle arrest. The regulatory effects of wild Baicalin on the AKR1B10 and PI3K/AKT signaling pathways appear to be critical for its inhibitory effects on HCC cell proliferation. These results provide new insights into the mechanism of action of wild Baicalin and support its potential as a therapeutic approach for HCC treatment.

Citing Articles

Exploring a new chapter in traditional Chinese medicine: The potential of in liver cancer treatment.

Du H, Chen H, Zhao Y World J Clin Oncol. 2024; 15(12):1520-1527.

PMID: 39720650 PMC: 11514369. DOI: 10.5306/wjco.v15.i12.1520.

References

Yang N, Zhao Y, Wang Z, Liu Y, Zhang Y . Scutellarin suppresses growth and causes apoptosis of human colorectal cancer cells by regulating the p53 pathway. Mol Med Rep. 2016; 15(2):929-935. DOI: 10.3892/mmr.2016.6081. View

Xiao W, Ren L, Chen Z, Fang L, Zhao Y, Lack J . Toward best practice in cancer mutation detection with whole-genome and whole-exome sequencing. Nat Biotechnol. 2021; 39(9):1141-1150. PMC: 8506910. DOI: 10.1038/s41587-021-00994-5. View

Morana O, Wood W, Gregory C . The Apoptosis Paradox in Cancer. Int J Mol Sci. 2022; 23(3). PMC: 8836235. DOI: 10.3390/ijms23031328. View

Miricescu D, Totan A, Stanescu-Spinu I, Badoiu S, Stefani C, Greabu M . PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects. Int J Mol Sci. 2020; 22(1). PMC: 7796017. DOI: 10.3390/ijms22010173. View

Qu J, Li J, Zhang Y, He R, Liu X, Gong K . AKR1B10 promotes breast cancer cell proliferation and migration via the PI3K/AKT/NF-κB signaling pathway. Cell Biosci. 2021; 11(1):163. PMC: 8379827. DOI: 10.1186/s13578-021-00677-3. View

Li X, Wang C . From bulk, single-cell to spatial RNA sequencing. Int J Oral Sci. 2021; 13(1):36. PMC: 8593179. DOI: 10.1038/s41368-021-00146-0. View

DiStefano J, Davis B . Diagnostic and Prognostic Potential of AKR1B10 in Human Hepatocellular Carcinoma. Cancers (Basel). 2019; 11(4). PMC: 6521254. DOI: 10.3390/cancers11040486. View

Zhou Z, Zhao Y, Gu L, Niu X, Lu S . Inhibiting proliferation and migration of lung cancer using small interfering RNA targeting on Aldo-keto reductase family 1 member B10. Mol Med Rep. 2017; 17(2):2153-2160. PMC: 5783456. DOI: 10.3892/mmr.2017.8173. View

Shi Y, Wang Y, Yang R, Zhang W, Zhang Y, Feng K . Glycosylation-related molecular subtypes and risk score of hepatocellular carcinoma: Novel insights to clinical decision-making. Front Endocrinol (Lausanne). 2023; 13:1090324. PMC: 9807760. DOI: 10.3389/fendo.2022.1090324. View

10.

Kibria G, Hatakeyama H, Harashima H . Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system. Arch Pharm Res. 2013; 37(1):4-15. DOI: 10.1007/s12272-013-0276-2. View

11.

Chen J, Zhang S . Liver cancer epidemic in China: past, present and future. Semin Cancer Biol. 2010; 21(1):59-69. DOI: 10.1016/j.semcancer.2010.11.002. View

12.

Jumper N, Hodgkinson T, Arscott G, Har-Shai Y, Paus R, Bayat A . The Aldo-Keto Reductase AKR1B10 Is Up-Regulated in Keloid Epidermis, Implicating Retinoic Acid Pathway Dysregulation in the Pathogenesis of Keloid Disease. J Invest Dermatol. 2016; 136(7):1500-1512. DOI: 10.1016/j.jid.2016.03.022. View

13.

Jiang N, Dai Q, Su X, Fu J, Feng X, Peng J . Role of PI3K/AKT pathway in cancer: the framework of malignant behavior. Mol Biol Rep. 2020; 47(6):4587-4629. PMC: 7295848. DOI: 10.1007/s11033-020-05435-1. View

14.

Zheng W, Jiang F, Shan J, Wang Y, Jia Y, Guo Q . Levels of serum IgG subclasses in patients with liver disease: A retrospective study. Exp Ther Med. 2020; 21(1):45. PMC: 7706388. DOI: 10.3892/etm.2020.9476. View

15.

Endo S, Hu D, Suyama M, Matsunaga T, Sugimoto K, Matsuya Y . Synthesis and structure-activity relationship of 2-phenyliminochromene derivatives as inhibitors for aldo-keto reductase (AKR) 1B10. Bioorg Med Chem. 2013; 21(21):6378-84. DOI: 10.1016/j.bmc.2013.08.059. View

16.

Song D, Lee J, Lee E, Jung S, Nho C, Cha K . Inhibitory effects of polyphenols isolated from Rhus verniciflua on Aldo-keto reductase family 1 B10. BMB Rep. 2010; 43(4):268-72. DOI: 10.5483/bmbrep.2010.43.4.268. View

17.

Saeidian A, Youssefian L, Vahidnezhad H, Uitto J . Research Techniques Made Simple: Whole-Transcriptome Sequencing by RNA-Seq for Diagnosis of Monogenic Disorders. J Invest Dermatol. 2020; 140(6):1117-1126.e1. PMC: 8722382. DOI: 10.1016/j.jid.2020.02.032. View

18.

Liu W, Cheng Y, Liu Z, Liu C, Cattell R, Xie X . Preoperative Prediction of Ki-67 Status in Breast Cancer with Multiparametric MRI Using Transfer Learning. Acad Radiol. 2020; 28(2):e44-e53. DOI: 10.1016/j.acra.2020.02.006. View

19.

de Visser K, Joyce J . The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell. 2023; 41(3):374-403. DOI: 10.1016/j.ccell.2023.02.016. View

20.

Rascio F, Spadaccino F, Rocchetti M, Castellano G, Stallone G, Netti G . The Pathogenic Role of PI3K/AKT Pathway in Cancer Onset and Drug Resistance: An Updated Review. Cancers (Basel). 2021; 13(16). PMC: 8394096. DOI: 10.3390/cancers13163949. View